Data from EMC - Curated by Toby Galbraith - Last updated 21 April 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

Visit Allergic Rhinitis


Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Visit Transplantation


Related Content

More information

Category Value
Agency product number EMEA/H/C/001068
Orphan designation No
Date First Approved 16-10-2009
Type Medicinal product subject to medical prescription
Marketing authorisation holder Novartis Europharm Ltd.